Title |
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial
|
---|---|
Published in |
BMC Cancer, March 2019
|
DOI | 10.1186/s12885-019-5498-3 |
Pubmed ID | |
Authors |
Maria Di Bartolomeo, Monica Niger, Federica Morano, Salvatore Corallo, Maria Antista, Stefano Tamberi, Sara Lonardi, Samantha Di Donato, Rossana Berardi, Mario Scartozzi, Giovanni Gerardo Cardellino, Francesco Di Costanzo, Lorenza Rimassa, Alberto Gianluigi Luporini, Raffaella Longarini, Alberto Zaniboni, Alessandro Bertolini, Gianluca Tomasello, Graziella Pinotti, Giorgio Scagliotti, Giampaolo Tortora, Andrea Bonetti, Andrea Spallanzani, Giovanni Luca Frassineti, Davide Tassinari, Francesco Giuliani, Saverio Cinieri, Evaristo Maiello, Claudio Verusio, Sergio Bracarda, Vincenzo Catalano, Michele Basso, Libero Ciuffreda, Ferdinando De Vita, Hector Soto Parra, Lorenzo Fornaro, Marta Caporale, Filippo de Braud, Filippo Pietrantonio |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 65 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Doctoral Student | 8 | 12% |
Student > Bachelor | 7 | 11% |
Unspecified | 4 | 6% |
Other | 4 | 6% |
Student > Ph. D. Student | 4 | 6% |
Other | 13 | 20% |
Unknown | 25 | 38% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 19 | 29% |
Nursing and Health Professions | 4 | 6% |
Unspecified | 4 | 6% |
Biochemistry, Genetics and Molecular Biology | 3 | 5% |
Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
Other | 8 | 12% |
Unknown | 24 | 37% |